With the advent of next generation sequencing in cancer care, patients’ tumors can be genomically profiled and specific genetic alterations can be targeted with precision medicine drugs. However, the abundance of patient sequencing data coupled with complex clinical trial eligibility has made it challenging to match patients to precision medicine trials. To facilitate interpretation of complex tumor sequencing data and clinical trial genomic eligibility criteria, we developed MatchMiner, an open-source platform to computationally match cancer patients to precision medicine clinical trials. MatchMiner has several modes of clinical use: (1) patient-centric, where clinicians look up trial matches for their patient, (2) trial-centric, where clinical trial investigators identify patients for their clinical trials, and (3) trial search, where clinicians identify available trials based on any criteria, including external genomic reports. To support users in all three modes, MatchMiner also displays full genomic reports for patients and detailed trial information in user-friendly formats. MatchMiner trial matching is performed via the MatchEngine, an algorithm that computes matches based on patient genomic and clinical data and trial eligibility criteria. The MatchEngine accepts many different data inputs for patient-trial matching, and is easily customized to work with data available at any institution. At Dana-Farber Cancer Institute (DFCI), MatchMiner supports the following data: 1) patient-specific genomic sequencing data, including mutations, copy number alterations, structural variants, tumor mutational burden and mutational signatures including mismatch repair deficiency or microsatellite instability, 2) patient-specific clinical data, including primary cancer type, gender, age, and vital status, and 3) trial eligibility criteria including genomic targets, cancer type, and age. Unique to MatchMiner, each trial’s eligibility criteria is encoded in clinical trial markup language (CTML), a structured format that encodes detailed information about a trial and utilizes boolean logic to encode inclusion and exclusion criteria. Although MatchMiner has been operational at DFCI since early 2017, its impact on patient care has not yet been extensively studied. Thus far, MatchMiner has facilitated 181 precision medicine trial consents (MatchMiner consents, MMC) for 159 patients. To quantify MatchMiner’s impact on trial consent, we retrospectively measured time from genomic sequencing report date to trial consent date for a subset of the 181 MMC (166 MMC). We compared time to trial consent date for the 166 MMC to a group of 353 consents for the same trials not facilitated by MatchMiner (non-MatchMiner consents, non-MMC). MMC consented to trials 22% faster (P=0.004, median=195 days, IQR=85-34) than non-MMC (median=250 days; IQR=99-491). Thus, clinical use of MatchMiner decreased time to enroll in a precision medicine study, and suggests that use of precision medicine trial matching tools such as MatchMiner are important for the future of patient care.
Citation Format: Harry Klein, Tali Mazor, Priti Kumari, James Lindsay, Andrea Ovalle, Pavel Trukhanov, Joyce Yu, Michael Hassett, Ethan Cerami. MatchMiner: An open-source platform for cancer precision medicine [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P160.